EVerZom
EVerZom is a nanomedicine biotech company providing a large scale of GMP manufacturing platform of extracellular vesicles.
EVerZom has raised €11M across 2 funding rounds from 7 investors, most recently a round in Oct 2025. Based in Paris, France; founded 1919; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€11M
€11,100,000
Funding rounds
2
Investors
7
distinct backers
Active since
2020-12
latest 2025-10
Funding by year
EUR raised per yearEVerZom — funding by year — interactive chart.
Data table
| EVerZom — funding by year | |
|---|---|
| 2020 | €1.1M |
| 2025 | €10M |
Signals
High confidenceRaise-next likelihood46
base rate 30% for Other
- ▲ In typical raise window
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood6
base rate 11% (2+ rounds)
- ▼ Old (107y) — past typical exit age
- ▲ Recently backed by strong-exit-track investors
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-10-14 | Other | €10M | Aloe Private Equity,Capital Cell platform,Capital Grand Est,Family Offices,Paris Business Angels,Sorbonne Venture+1 more | View deal → |
| 2020-12-01 | Other | €1.1M | — | View deal → |
Investors
7Related news
Similar companies
same sector or country- Mistral AI€6.5BFrance · AI
- Automotive Cells Company (ACC)€4.4BFrance · Transportation
- Philips€2.6BNetherlands · Healthtech
- Verkor€2.4BFrance · Energy
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
Global coverage: FundingData